Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dade Behring and Third Wave sign icensing deal:

This article was originally published in Clinica

Executive Summary

Dade Behring and Third Wave Technologies have formed a non-exclusive, royalty-bearing, cross-licensing agreement. As a result, Dade has the right to develop in vitro diagnostic tests for blood clotting disorders and to detect drug resistant infectious diseases organisms based on Third Wave's Invader patents. Dade has granted Third Wave freedom to operate under certain of its patents. Invader assays have a high level of specificity, simplicity and cost effectiveness, the companies claim. In addition, they do not have the carryover contamination complications associated with PCR, they maintain.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel